ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Biotech Resilience | ICON's Non-COVID segments outperform expectations, showcasing resilience amid industry shifts and strong demand from pharmaceutical giants |
Financial Maneuvers | Debt refinancing boosts 2024 EPS guidance, demonstrating proactive capital management and enhancing financial flexibility |
Strategic Growth Path | Explore ICON's focus on biotech M&A, potentially driving innovation, service expansion, and market position strengthening |
Market Dynamics | Analysts project EPS of $15.06-$15.15 for FY1 and $16.97-$17.31 for FY2, with an average price target of $353, reflecting industry challenges and opportunities |
Metrics to compare | ICLR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipICLRPeersSector | |
---|---|---|---|---|
P/E Ratio | 23.4x | 13.2x | −0.6x | |
PEG Ratio | 0.53 | −0.64 | 0.00 | |
Price/Book | 1.8x | 1.4x | 2.6x | |
Price / LTM Sales | 2.1x | 3.0x | 3.2x | |
Upside (Analyst Target) | 31.4% | 21.1% | 43.6% | |
Fair Value Upside | Unlock | 8.2% | 5.8% | Unlock |